Followers | 377 |
Posts | 17235 |
Boards Moderated | 3 |
Alias Born | 03/07/2014 |
Friday, August 01, 2014 7:42:16 PM
There is little or no "trial" spending going on, as the total "R&D" expense line is about $5K a month. Look at past filings when they were running actual "trials", as in FDA type trials. That R&D line was many multiples of that. Just in the same period 2013, it was $172K versus this paltry $15K.
They can't "hide" or "wash" supposed "trial spending" under some mysterious part of their financial statements or hidden place in the 10-Q? That's not how it works.
There's some good web sites and good books at any library on reading and understanding things like basic "financials" (commonly known as a set of financials or financial statements for a business)- typically a balance sheet, an income statement, a statement of cash flows and probably stockholder's equity. There's a few variations, but those are the jest of a typical set of "financials". That's the "snap shot" of pretty much everything key in terms of money coming in, money going out, expenses, income/revenue, interest paid, short and long term debt, etc. In this 10-Q filing, it's pretty much pages 4, 5, 6 and 7. Read those.
ZenaTech, Inc. (NASDAQ: ZENA) Launchs IQ Nano Drone for Commercial Indoor Use • HALO • Oct 10, 2024 8:09 AM
CBD Life Sciences Inc. (CBDL) Targets Alibaba as the Next Retail Giant for Wholesale Expansion of Top-Selling CBD Products • CBDL • Oct 10, 2024 8:00 AM
Foremost Lithium Announces Option Agreement with Denison on 10 Uranium Projects Spanning over 330,000 Acres in the Athabasca Basin, Saskatchewan • FAT • Oct 10, 2024 5:51 AM
Element79 Gold Corp. Reports Significant Progress in Community Relations and Development Efforts in Chachas, Peru • ELEM • Oct 9, 2024 10:30 AM
Unitronix Corp Launches Share Buyback Initiative • UTRX • Oct 9, 2024 9:10 AM
BASANITE INDUSTRIES, LLC RECEIVES U.S. PATENT FOR ITS BASAFLEX™ BASALT FIBER COMPOSITE REBAR AND METHOD OF MANUFACTURING • BASA • Oct 9, 2024 7:30 AM